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Abstract: Somatic serine/threonine kinase 11 (STK11) also known as 
liver kinase B1 (LKB1) is a tumor suppressor gene and ranks as the third 
most frequently mutated gene in lung adenocarcinoma. However, cur-
rent molecular testing guidelines recommend evaluating for epidermal 
growth factor receptor mutations and ALK fusions to guide therapy in 
all patients with advanced stage adenocarcinoma, regardless of gender, 
race, or smoking history. Identifying alternative “driver” mutations and 
using actionable targeted pharmacotherapy is a key approach to pro-
viding effective individualized medical care. The analytical sensitivity 
and parallel multigene approach of targeted next-generation sequenc-
ing is an attractive methodology for use for cytology specimens. The 
presented lung adenocarcinoma study revealed that STK11 mutations 
alone and concomitant KRAS/STK11 mutations were identified in 
18.2% and 4.5% of solitary adrenal metastases, respectively. Molecular 
profiling of epidermal growth factor receptor tyrosine kinase inhibitor 
resistant tumors may help to identify patients who would most benefit 
from alternative single or dual pathway inhibition potentially leading to 
a revision in current molecular testing guidelines.
Key Words: Lung adenocarcinoma, Adrenal metastasis, Cytology, 
Multigene profile, Targeted therapy.
(J Thorac Oncol. 2015;10: 531–534)
KRAS, ALK, BRAF, and epidermal growth factor receptor (EGFR) are oncogenic alterations found in 50% of lung 
adenocarcinomas. Some tumors with EGFR mutations or 
ALK gene rearrangements are responsive to targeted therapy, 
whereas KRAS and BRAF mutations predict resistance to 
such therapies. The ability to individualize therapies based 
on genetic testing of tumors represents significant progress. 
Other gene rearrangements (ROS1 and RET) have been iden-
tified as therapeutic targets in lung cancer, but are rare events. 
Little emphasis has been placed on mutated tumor suppressor 
genes. The Tumor Sequencing Project identified 26 signifi-
cantly mutated oncogenes and tumor suppressor genes. The 
most frequently identified tumor suppressor genes were TP53 
(70%), STK11 (18%), and CDKN2A (5%).1
Somatic serine/threonine kinase 11 (STK11) encodes the 
serine/threonine protein kinase and is part of the STK11/AMPK/
mTOR signaling pathway. It has been identified in the histologi-
cal spectrum of sporadic adenocarcinoma, squamous cell, and 
large-cell carcinoma of the lung. It has been identified in up to 
33% of primary lung adenocarcinomas and 12% of brain metas-
tases.2–4 Patients with concomitant KRAS/STK11 mutations have 
a poorer prognosis when compared with patients with KRAS-
mutated but STK11 wild-type adenocarcinoma, suggesting that 
loss of STK11 induces a more aggressive tumor phenotype.5 The 
loss of STK11 in melanoma and cervical cancer promotes wide-
spread and high-grade metastasis.6,7 In murine models, STK11-
deficient tumors demonstrated more frequent metastasis when 
compared with tumors with TP53 alterations.8
Concomitant STK11/KRAS mutant non–small-cell lung 
cancer cell lines are sensitive to dual threonine and tyrosine 
recognition kinase (MEK) inhibitors and may be suitable 
for mTOR-targeted therapies.9 Phenformin, a mitochondrial 
inhibitor and analog of metformin, has also been proposed as 
a cancer metabolism–based therapeutic strategy to selectively 
target STK11-mutated tumors.10 Furthermore, deoxythymi-
dylate kinase is an additional potential therapeutic target for 
STK11 mutant tumors.11
We have previously published our experience with opti-
mal fine-needle aspirate and touch preparation smear cellular-
ity characteristics for successful theranostic next-generation 
sequencing and the presented patients represent an unpub-
lished subset of that data.12 In cytologically proven adrenal 
metastasis from patients with treatment naive lung adenocar-
cinoma, we aimed to identify the prevalence of STK11 mutant 
status and concomitant STK11/KRAS mutant status with a 
targeted next-generation sequencing-based approach using a 
50-gene cancer hotspot panel.
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MATERIALS AND METHODS
Twenty-two adrenal gland cytology specimens represent-
ing a solitary metastatic site from lung adenocarcinoma obtained 
either by endoscopic ultrasound fine-needle aspiration or com-
puted tomography guidance fulfilled cytology smear selection 
and DNA quality criteria. Subsequently, multiplex polymerase 
chain reaction was performed by amplifying 30 ng of DNA 
with the Ion AmpliSeq Cancer Hotspot Panel v2 and the Ion 
AmpliSeq Library Kit 2.0 (Life Technologies, Carlsbad, CA) 
per manufacturer’s instructions. This AmpliSeq kit targets 207 
amplicons (>2800 potential mutations) within 50 cancer-asso-
ciated genes, including: ABL1, AKT1, ALK, APC, ATM, BRAF, 
CDH1, CDKN2A, CSF1R, CTNNB1, EGFR, ERBB2, ERBB4, 
EZH2, FBXW7, FGFR1, FGFR2, FGFR3, FLT3, GNAQ, GNAS, 
GNA11, HNF1A, HRAS, IDH1, IDH2, JAK2, JAK3, KDR, KIT, 
KRAS, MET, MLH1, MPL, NOTCH1, NPM1, NRAS, PDGFRA, 
PIK3CA, PTEN, PTPN11, RB1, RET, SMAD4, SMARCB1, 
SMO, SRC, STK11, TP53, and VHL (Supplemental Digital 
Content, http://links.lww.com/JTO/A731).
RESULTS
Patient Characteristics
The treatment naïve adenocarcinoma patient cohort was 
comprised of 12 men and 10 women (age, 69.9 ± 11.2 years) 
and they were followed for 10.6 months (interquartile range 
[IQR], 6.6–20.8) after cytologic diagnosis of adrenal metasta-
sis. This group included current smokers (n = 14 [77.8%] with 
a 50-year pack history [IQR, 30–68]), former smokers (n = 6 
[27.3%] with a 30-year pack history [IQR, 7.5–35]), and never 
smokers (n = 2 [11%]). Overall mortality (n = 18 [81.9%]) 
was observed at 9.2 months (IQR, 3.4–12.9) after diagnosis.
Cytology Mutation Profiling
Subsequent review identified 27 pathogenic alterations in 
eight of the 50 tested genes. Pathogenic alterations were identi-
fied in 19 (86.4%) of 22 patients, with a median of 1 (1–2) alter-
ation per patient. Specific pathogenic alterations and respective 
frequencies are presented in Table 1. Four (18.2%) patients’ 
tumors possessed STK11 mutations (Table 2). Concomitant 
KRAS/STK11 mutations were identified in one patient (4.5%). 
EGFR and KRAS pathogenic alterations were mutually exclu-
sive. There was no difference in age, gender, smoking status, or 
disease-related mortality, between STK11 mutant and STK11 
wild-type adenocarcinoma patients (Table 3).
Exploring Customized Genotype 
Directed Therapy
EGFR mutations were identified in two patients (11%), 
making them eligible for EGFR-tyrosine kinase inhibitor (TKI) 
therapy. All four STK11 mutant patients were EGFR, TP53, RB1, 
TABLE 1.  Stage IV (M1b) Treatment Naive Adenocarcinoma Pathogenic Alteration Distribution and Frequency
ABL1, N = 0 EZH2, N = 0 JAK3, N = 0 PTEN, N = 1 (4.5%)
AKT1, N = 0 FBXW7, N = 0 IDH2, N = 0 PTPN11, N = 0
ALK, N = 0 FGFR1, N = 0 KDR, N = 0 RB1, N = 0
APC, N = 0 FGFR2, N = 0 KIT, N = 0 RET, N = 1 (4.5%)
ATM, N = 0 FGFR3, N = 0 KRAS, N = 7 (31.8%) SMAD4, N = 0
BRAF, N = 0 FLT3, N = 0 MET, N = 0 SMARCB1, N = 0
CDH1, N = 0 GNA11, N = 0 MLH1, N = 0 SMO, N = 0
CDKN2A (p16), N = 0 GNAS, N = 1 (4.5%) MPL, N = 0 SRC, N = 0
CSF1R, N = 0 GNAQ, N = 0 NOTCH1, N = 0 LKB1, N = 4 (18.2%)
CTNNB1c (β-catenin), N = 0 HNF1A, N = 0 NPM1, N = 0 TP53, N = 10 (45%)
EGFR, N = 2 (11%) HRAS, N = 0 NRAS, N = 0 VHL, N = 0
ERBB2 (HER2), N = 0 IDH1, N = 0 PDGFRA, N = 0
ERBB4, N = 0 JAK2, N = 0 PIK3CA, N = 1 (4.5%)
Bold indicates the gene mutations identified.
TABLE 2. STK11 Mutational Profile
Patient 1 Patient 2 Patient 3 Patient 4
Age (yr) 73 63 87 76
Gender Female Male Male Female
Smoking Former Current Current Current
Pack-years NA 75 50 50
Laterality Bilateral Left Right Left
Therapy Unknown Carboplatin, taxol, and avastin Carboplatin and taxol Declined therapy
Overall survival (mo) 8.4 22.7 2.6 6.6
STK11 profile c.465-2A>T c.465-1G>T c.108C>G, p.Tyr36X c.97G>T, p.Glu33X
Co-mutations None KRAS: c.35G>A, p.Gly12Asp;  
RET: c.1946C>T, p.Ser649Leu
PTEN: c.973C>T, p.Leu325Phe None
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CDKN2A, BRAF, PTPN11, ERBB2, NRAS, CTNNB1, AKT1, 
and MEK wild type. Standard EGFR-TKI therapy is predicted to 
have limited therapeutic value for this mutational profile.
DISCUSSION
In clinical practice, it is critical to accurately define 
patients with tumor phenotype subpopulations that are most 
likely to benefit from pharmacologic intervention. EGFR and 
ALK testing has become essential in the treatment of patients 
with advanced non–small-cell lung cancer, present in up to 50% 
of Asian lung adenocarcinomas populations in contrast to only 
5% to 15% in a non-Asian population.13–16 This underscores the 
need to search for other “druggable” mutations or concomitant 
mutations to develop new target opportunities. STK11 ranks 
as the third most frequently mutated gene in lung adenocarci-
noma, following TP53 and KRAS. The presented study revealed 
that STK11 mutations and concomitant KRAS/STK11 mutations 
were identified in 18.2% and 4.5% of solitary adrenal adeno-
carcinoma metastases, respectively. The STK11 mutation fre-
quency is concordant with the results of the Tumor Sequencing 
Project. Due to the relative high frequency of STK11 mutations 
and involvement of STK11 in the mTOR signaling pathway, 
this presents a potential opportunity for development of new tar-
geted therapy. If managed solely with cytotoxic chemotherapy, 
even isolated adrenal metastases progress to death with reported 
survival of only 6 to 9 months.17 By using a multigene cancer 
panel, molecular profiling of EGFR tyrosine kinase inhibitor 
resistant tumors may help to identify a subset of patients who 
would most benefit from alternative single or dual pathway 
inhibition therapy, i.e., insulin-like growth factor inhibitors and/
or MEK/PI3K/AKT/mTOR inhibition, especially in the context 
of clinical trials. Future studies with incorporation of RNAseq 
or targeted or whole exome sequencing analysis will further 
improve the treatment options for advanced cancer patients 
with actionable mutations.
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Erratum
Early-Stage Lung Cancer: 40s Anniversary: Erratum
The title of the article beginning on page 1434 of the October 2014 issue appeared incorrectly as Early-Stage Lung Cancer: 40s Anniversary. The correct title 
for this article is Early Stage Lung Cancer: Progress in the Last 40 Years.
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